# ATALANTE: HCP commentary report

> 50 verified statements (1 from clinicians verified by NPI or staff page) from 16 commentary sources · 4 findings · updated Oct 31, 2026

## Report

- Trial: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
- NCT ID: NCT02891824
- Registry: https://clinicaltrials.gov/study/NCT02891824
- Sponsor: ARCAGY/ GINECO GROUP
- Phase: Phase 3
- Status: Completed
- Drugs tested: atezolizumab plus bevacizumab
- Indication: platinum-sensitive ovarian cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: 0c28fdeb00a949052b3838d8799c0bd4a4997e624d5ac012e7b9ee6f7b534e3b

## Counts

- HCP commentary sources screened: 40
- Sources cited by verified statements: 17
- Verified statements: 50
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 1
- Findings: 4
- Named people in screened sources (unnamed speakers and accounts not counted): 9
- Voices cited: 9
- Cited voices identity-verified: 5
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

ATALANTE asks whether adding atezolizumab to platinum chemotherapy plus bevacizumab can delay progression in platinum-sensitive recurrent ovarian cancer. Commentary comes from X posts and video interviews on X and YouTube. Debate centers on how survival-data maturity and hierarchical testing frame contested interpretation of exploratory overall survival and its implications for routine atezolizumab use. Selection of patients for immunotherapy in this setting remains unresolved.

## Open Medical Affairs question

How should Medical Affairs explain patient-relevant exploratory OS without implying confirmatory efficacy, routine checkpoint-inhibitor use or validated patient selection?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Exploratory OS: clinical importance and implications for routine use
- F2. Maturity and hierarchical testing frame the dispute over how OS should be interpreted
- F3. Subgroup hints, PD-L1 findings and the search for patient selection
- F4. Reactions to repeated negative studies and proposed immune research directions

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 9 | 8 | 7 | 6 | recorded | 2 |
| F2 | 12 | 8 | 6 | 4 | recorded | 3 |
| F3 | 8 | 6 | 3 | 2 | none recorded | 3 |
| F4 | 14 | 12 | 9 | 7 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 0 | 0 | 0 | 2 | 10 | 0 | 3 posts and articles, 3 podcasts and video, 1 publication | yes |
| F2 | 8 | 0 | 0 | 0 | 4 | 12 | 0 | 4 posts and articles, 1 podcast or video, 1 publication | yes |
| F3 | 6 | 0 | 1 | 1 | 0 | 8 | 0 | 2 podcasts and video, 1 publication | yes |
| F4 | 8 | 1 | 0 | 1 | 4 | 15 | 1 | 6 posts and articles, 2 podcasts and video, 1 publication | yes |

### Trial dimensions

- Primary endpoint: Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1: F1 (4 shared claims), F2 (3 shared claims), F4 (2 shared claims)
- Secondary endpoint: Efficacy: Overall survival (OS): F1 (6 shared claims), F2 (8 shared claims)
- Secondary endpoint: Efficacy: Time from date randomization to second subsequent therapy or date of death (TSST) whichever come first: no finding draws on it directly
- Secondary endpoint: patient reported outcome variables: no finding draws on it directly
- Secondary endpoint: Adverse events: no finding draws on it directly
- Population and setting: F3 (4 shared claims), F4 (1 shared claims)
- The comparison: F4 (4 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F1 (1 shared claims), F2 (4 shared claims), F4 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Maturity and hierarchical testing frame the dispute over how OS should be interpreted

A YouTube interview addresses how to interpret overall survival in relation to follow-up and the trial’s endpoint-testing plan.

Source: YouTube video, 2024-10-23.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 50 | Paid |
| Trial aspects mapped | 13 | Free |
| Sources with links | 17 | Counts free |
| Speaker attribution for cited voices | 9 | Paid |

## Trial aspects

9 discussed · 4 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1 | discussed | 7 | 7 |
| Secondary endpoint: Efficacy: Overall survival (OS) | discussed | 12 | 9 |
| Secondary endpoint: Efficacy: Time from date randomization to second subsequent therapy or date of death (TSST) whichever come first | no commentary found | 0 | 0 |
| Secondary endpoint: patient reported outcome variables | no commentary found | 0 | 0 |
| Secondary endpoint: Adverse events | no commentary found | 0 | 0 |
| Population and setting | discussed | 6 | 3 |
| The comparison | discussed | 5 | 4 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 6 | 4 |
| Clinical importance, routine-use implications and market expectations | discussed | 6 | 5 |
| Predictive markers and biopsy-led translational research | discussed | 4 | 2 |
| Combination rationale and accumulated disappointment with checkpoint inhibition | discussed | 8 | 7 |
| AGO-OVAR 2.29/ENGOT-ov34 comparison and alternative immune research approaches | discussed | 3 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 34 | 12 |
| YouTube | 3 | 3 |
| X videos | 1 | 1 |
| Bluesky threads | 1 | 0 |
| Podcasts | 1 | 0 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2022-09-09 to 2026-10-14
- Cited window: 2022-09-09 to 2026-10-14
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
- Also known as: ENGOT-ov29
- Registry: NCT02891824 (https://clinicaltrials.gov/study/NCT02891824)
- Study IDs: GINECO-OV236b
- Sponsor: ARCAGY/ GINECO GROUP
- Collaborators: Hoffmann-La Roche
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Completed
- Enrollment: 614 (actual)
- Start: 2016-09-22 (actual)
- Primary completion: 2021-10-15 (actual)
- Primary endpoint: Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1 (An average of 19 months)
- Intervention: atezolizumab + avastin + platinum-based chemotherapy (drug)
- Intervention: placebo + avastin + platinum-based chemotherapy (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources include organizational accounts and relayed article or presentation wording. Repetition and reposting do not establish independent HCP agreement.
- Clinical roles are not established for every named social-media author. Account names are not treated as proof of credentials or specialty.
- The speaker of the relevant AGO229-ENGOT-ov34 interview passages cannot be named from the available speech; publisher identification alone does not establish who said those words.
- The full final-OS report was not available for assessment. Later survival findings are described through posts and interviews, while the available results publication reports earlier, immature OS.
- A separate protocol and exact regulatory labels for the studied combinations were not available in the sources reviewed. A speaker's expectation about market entry is not an established regulatory outcome.
- No HCP commentary on TSST, patient-reported outcomes, adverse-event interpretation or tolerability was identified in the assessed material. This absence does not establish an absence of clinical concern.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition, corrected 2026-10-31
  - Correction 2026-10-31: Corrected to match the delivered report: per-finding counts; the sample findings; the report description. The trial's name is spelled as its investigators write it, “ATALANTE” (NCT02891824), outside quotations (was “ATALANT”, “ATALANTA”, “Atalanta”). An editorial bracket follows a transcription-garbled trial name in quotations: “Atalanta [ATALANTE]”.

Last checked for new commentary 2026-10-31. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (50 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (5 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/atalante-nct02891824
- Agents: POST https://www.erudio.com/api/orders with {"report": "atalante-nct02891824", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=atalante-02891824

## Cite

Erudio Health. ATALANTE (NCT02891824): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/atalante-nct02891824

## Machine access

- JSON: https://www.erudio.com/reports/atalante-nct02891824.json
- Markdown: https://www.erudio.com/reports/atalante-nct02891824.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "atalante-02891824"}`